Saltar al contenido

Biogen Inc. (BIIB) stock: revenue, earnings & dividend

Biogen Inc. (BIIB, Nasdaq): revenue, earnings, dividend and balance sheet from official SEC filings.

Stock screener BIIB · Nasdaq Pharma & Biotech US-MA

Key figures

Fiscal year
2025
Revenue
9.89 bn $
Revenue growth
2.2 %
Revenue growth 5y (p.a.)
-6 %
Net income
1.29 bn $
Net margin
13.1 %
Operating margin
–
Earnings per share (diluted)
8.79 $
Dividend per share
–
Payout ratio
–
Consecutive dividend years
–
Consecutive dividend raises
–
Dividend growth 5y (p.a.)
–
Total assets
29.4 bn $
Equity
18.3 bn $
Equity ratio
62 %
Return on equity
7.1 %
Cash
3.01 bn $
Operating cash flow
2.2 bn $
Free cash flow
2.05 bn $
Shares outstanding
147,820,223

History

Revenue by fiscal year

2016 11.4 bn $
2017 12.3 bn $
2018 13.5 bn $
2019 14.4 bn $
2020 13.4 bn $
2021 11 bn $
2022 10.2 bn $
2023 9.84 bn $
2024 9.68 bn $
2025 9.89 bn $

Net income by fiscal year

2016 3.7 bn $
2017 2.54 bn $
2018 4.43 bn $
2019 5.89 bn $
2020 4 bn $
2021 1.56 bn $
2022 3.05 bn $
2023 1.16 bn $
2024 1.63 bn $
2025 1.29 bn $
YearRevenueNet incomeEPSDividend per shareOperating cash flow
20259.89 bn $1.29 bn $8.79 $–2.2 bn $
20249.68 bn $1.63 bn $11.18 $–2.88 bn $
20239.84 bn $1.16 bn $7.97 $–1.55 bn $
202210.2 bn $3.05 bn $20.87 $–1.38 bn $
202111 bn $1.56 bn $10.40 $–3.64 bn $
202013.4 bn $4 bn $24.80 $–4.23 bn $
201914.4 bn $5.89 bn $31.42 $–7.08 bn $
201813.5 bn $4.43 bn $21.58 $–6.19 bn $
201712.3 bn $2.54 bn $11.92 $–4.55 bn $
201611.4 bn $3.7 bn $16.93 $–4.59 bn $

Data from XBRL filings at the SEC, processed automatically, no guarantee. Not investment advice. All filings at the SEC (EDGAR)